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Background: Alterations and senescence in bone marrow mesenchymal stromal cells of multiple myeloma patients
(MM-BMMSCs) have become an important research focus. However the role of senescence in the pathophysiology
of MM is not clear.
Methods: Correlation between senescence, cell cycle and microRNA expression of MM-BMMSCs (n = 89) was
analyzed. Gene expression analysis, copy number analysis and methylation specific PCR were performed by
Real-Time PCR. Furthermore, cyclin E1, cyclin D1, p16 and p21 genes were analyzed at the protein level using ELISA.
Cell cycle and senescence were analyzed by FACS. MiRNA transfection was performed with miR-485-5p inhibitor
and mimic followed by downstream analysis of senescence and cell cycle characteristics of MM-BMMSCs. Results were
analyzed by Mann–Whitney U test, Wilcoxon signed-rank test and paired t-test depending on the experimental set up.
Results: MM-BMMSCs displayed increased senescence associated β-galactosidase activity (SA-βGalA), cell cycle
arrest in S phase and overexpression of microRNAs. The overexpressed microRNAs miR-485-5p and miR-519d are
located on DLK1-DIO3 and C19MC, respectively. Analyses revealed copy number accumulation and hypomethylation
of both clusters. KMS12-PE myeloma cells decreased SA-βGalA and influenced cell cycle characteristics of MM-BMMSCs.
MiR-485-5p was significantly decreased in co-cultured MM-BMMSCs in connection with an increased methylation
of DLK1-DIO3. Modification of miR-485-5p levels using microRNA mimic or inhibitor altered senescence and cell
cycle characteristics of MM-BMMSCs.
Conclusions: Here, we show for the first time that MM-BMMSCs have aberrant methylation and copy number of
the DLK1-DIO3 and C19MC genomic region. Furthermore, this is the first study pointing that multiple myeloma
cells in vitro reduce both the senescence phenotype of MM-BMMSCs and the expression of miR-223 and miR-485-5p.
Thus, it is questionable whether senescence of MM-BMMSCs plays a pathological role in active multiple myeloma or is
more important when cell interaction with myeloma cells is inhibited. Furthermore, we found that MiR-485-5p,
which is located on the DLK1-DIO3 cluster, seems to participate in the regulation of senescence status and cell
cycle characteristics of MM-BMMSCs. Thus, further exploration of the microRNAs of DLK1-DIO3 could provide
further insights into the origin of the senescence state and its reversal in MM-BMMSCs.
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Multiple Myeloma (MM) is a B-cell malignancy charac-
terized by the accumulation of malignant plasma cells
(PC) within the bone marrow (BM) and the strong inter-
action between several cellular compartments [1].
BMMSCs support MM cell growth through different
direct and indirect factors leading to increased tumor sup-
port and possible generation of drug resistance [2-10].
Thus, the surrounding tumor microenvironment has
become a focal point of MM research. Several studies
have suggested the genesis of constitutive abnormalities
in MM-BMMSCs through interactions with MM cells
[11-14]. For instance development of a senescence-like
state in BMMSCs and thereby a modulated secretory
profile, worsened osteogenic differentiation potential
and inhibition of the T-cell proliferation were reported
[13,15]. Senescence is a cellular state associated with the
loss of proliferative capacity and changes in the secretion
of pro-inflammatory cytokines and growth factors [16].
Senescent BMMSCs display an increased senescence-
associated β-galactosidase activity (SA-βGalA) and irregu-
lar cell morphology. Usually the cell cycle of senescent
cells is arrested at the G1/S-transition point in combin-
ation with the overexpression of different cell cycle inhibi-
tors as p21 and p16. In spite of the aberrant growth
characteristics senescent cells remain metabolically active
and therefore the secretion of pro-inflammatory mediators
could promote tumorigenesis in neighboring premalignant
cells [17-19]. Although some reports describe constitutive
changes in MM-BMMSCs, the molecular mechanisms
and pathways that induce senescence-associated abnor-
malities are largely unknown. Furthermore it is not clear
whether alterations of MM-BMMSCs are important for
the interaction between stromal cells and MM cells or are
more an attendant phenomenon.
Two imprinted clusters in the human genome might
contribute to the generation of senescence and induc-
tion of cellular changes in MM-BMMSCs [20-23]. The
DLK1-DIO3 imprinted domain is located on chromo-
some 14q32.2 and expresses 53 microRNAs, whereas
the imprinted cluster C19MC is located on chromosome
19q13 and codes for 59 microRNAs [24-26]. Allelic ex-
pression of DLK1-DIO3 is controlled through methylation
of a regulatory region (IG-DMR) located about 15 kb up-
stream of the cluster and the expression of C19MC corre-
lates with the epigenetic modulation of a CpG-rich region
located about 17.6 kb upstream [26,27].
Up to now no data on the role of the senescent pheno-
type of MM-BMMSCs for the progression of MM are
available. Previously, we have shown that MM-BMMSCs
exhibit overexpression of distinct microRNAs and an
increased senescence phenotype as compared to healthy
donor BMMSCs [28]. To further address this point we an-
alyzed in this study the correlation between senescencestatus, cell cycle characteristics and microRNA expression
of MM-BMMSCs. We chose microRNAs, which were
previously reported to be deregulated in MM cells and
play a potential role in inflammation-induced cellular
senescence [21,29-32]. We further addressed the ques-
tion of whether interaction of MM-BMMSCs with MM
cells could modulate the cell cycle and senescence-like
state of MM-BMMSCs by altering the expression of
microRNA molecules. In this context we wanted to analyze
whether the premature senescence status of MM-BMMSCs
could be a specific effect induced by MM cells for increased
tumor support. MiR-485-5p, which is encoded by the
DLK1-DIO3 cluster, was found to be a potential modu-
lator of the cell cycle and senescence status of MM-
BMMSCs. Based on this observation we finally investigated
the effect of miR-485-5p mimics or inhibitor on the cell
cycle and SA-βGalA of MM-BMMSCs.
Methods
Patient and donor characteristics
BM samples from 89 patients with multiple myeloma
[n = 54 with MM at the time of diagnosis and n = 35 at
relapse] were included in the study. All patients had a
treatment indication. Written informed consent was ob-
tained from all patients and healthy donors in accordance
with the Declaration of Helsinki and the ethical guidelines
of the Charite University School of Medicine, which
approved this study (Votum No.: EA4/131/13). Twelve
bone marrow aspirates were received from healthy do-
nors (see Additional file 1: Table S1: Patients and Donor
Characteristics).
Isolation and cultivation of BMMSCs
BMMSCs from patients with MM (MM-BMMSCs) or
donors (HD-BMMSCs) were isolated by the classical adhe-
sion method and cultivated as previously described [33-35].
Non-hematopoietic cell characteristics were identified by
flow cytometry by absence of CD45 and CD34 and pres-
ence of CD105 and CD90 expression with antibodies from
Miltenyi Biotec. Data was acquired and analyzed with a
FACS Calibur Flow Cytometer (BD Biosciences) and
Flowing Software (Cell Imaging Core). Purity of isolated
BMMSCs ranged from 94% to 99.5% (see Additional file 2:
Figure S1: Purity of isolated BMMSCs).
Co-Cultures and transwell cultures of MM-BMMSCs
For co-cultures 5×104 MM-BMMSCs were seeded in a
6-well plate and incubated for 4 h. Then 5×104 KMS12-
PE myeloma cells were added followed by incubation for
72 h. After incubation KMS12-PE cells were removed
by rigorous pipetting and detachment was confirmed
by microscopy. In addition the absence of CD138+
cells was checked with FACS during cell cycle ana-
lysis. MM-BMMSCs were washed twice with PBS and
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myeloma cells were pelleted and re-suspended in TRIzol
for downstream analysis.
For transwell cultures (0.4 μM pore size, Corning)
2×104 MM-BMMSCs were seeded in the lower chamber
of a 12-well plate and incubated for 4 h. Then 2×104
KMS12-PE myeloma cells were added to the upper
chamber. Incubation was performed for 72 h.
Cultures without KMS12-PE cells served as negative
control for transwell cultures and co-cultures.
Detection of SA-βGalA
β-galactosidase activity was measured as previously re-
ported [36]. Data was acquired as described above and
analyzed using the median fluorescence intensity (MFI).
Co-cultures of HD-BMMSCs (n = 3) and HS-5 stromal
cells (n = 3, CRL-11882) were used as controls. In addition
β-galactosidase activity was analyzed using the “Senes-
cence cells Histochemical Staining Kit” (Sigma Aldrich) as
recommended by the manufacturer.
Cell cycle analysis
Cell analysis was performed using the “Cell cycle Assay
Kit” (Abcam) as recommended by the manufacturer. Data
was acquired using a logarithmic scale.
Quantitative Real-Time PCR (qPCR)
Total RNA was extracted using TRIzol as described previ-
ously [37]. RNA was treated with DNase (Ambion) and
poly(A)-polymerase (NEB) according to the manufacturer’s
instructions. 800 ng of RNA was used for cDNA synthe-
sis with a Transcriptor First Strand cDNA Synthesis Kit
(Roche) and 2 μl of poly(T)VN adaptor primer (10 pmol)
in a 20 μl reaction.
qPCR was performed with the FastStart Universal
SybrGreen Master Mix (Roche). MicroRNA detection
was performed as described [38]. GAP-DH and 5.8S
rRNA were chosen as housekeeping genes. All primers
and corresponding accession numbers are listed in
Additional file 3: Supplemental Methods; Table S2. QPCR
was carried out with the RotorGene 6000 Real-Time PCR
cycler using 1:5 diluted cDNA (8 ng) as template. Cycling
conditions are described in Additional file 2: Supplemental
Methods; Table S3. qPCR efficiencies were determined
using linear regression analysis [39,40] using LinRegPCR
software and relative quantifications were estimated with
the Pfaffl-method [41]. Received data was analyzed with
the Rotor Gene 6000 software.
Quantitative methylation-specific PCR (qMSP)
DNA isolation was performed using Puregene reagents
(Qiagen) according to the manufacturer’s instructions.
300 ng of genomic DNA was subjected to bisulfite treat-
ment with the EpiTect Fast Bisulfite Conversion Kit(Qiagen) as recommended in the manual. Primers are
described in Additional file 2: Supplemental Methods;
Table S2. Reactions were performed with 30 ng treated
DNA using SYBR Green Master Mix (Roche). Thermal
conditions were as described above. Quantification was
carried out using a standard curve generated using a
dilution series of fully methylated with unmethylated
DNA (Applied Biosystems). Each sample was analyzed
in duplicates and Ct-values above 32 were excluded.
Copy number (CN) variation assay
Three genomic regions located along each of the clusters
were chosen for CN estimations of DLK1-DIO3 and
C19MC. Assay numbers (qBiomarker Copy Number
Assays, Qiagen) are listed in Additional file 2: Supplemen-
tal Methods; Table S4. Genomic DNA of the stromal cell
line HS-5 (CRL-11882) was applied as a calibrator. Cyc-
ling was carried out as recommended by the manufac-
turer. Relative quantification was achieved by the ΔΔCt
method as described in the qBiomarker manual.
microRNA mimic and inhibitor experiments
MM-BMMSCs were seeded in a 6-well plate with 1–
2.5*105 cells/well. After incubation for 3 h cells were
transfected with 10 mM of miR-485-5p mimic, 100 mM
of miR-485-5p inhibitor or the appropriate negative control.
The mimic, inhibitor and corresponding negative controls
were all obtained from Qiagen AG. Transfections were per-
formed with the HiPerfect Transfection Reagent (Qiagen)
as recommended by the manufacturer. In addition, a trans-
fection control containing only the transfection reagent was
carried out. Transfected MM-BMMSCs were incubated
for 48 h before use for downstream analysis.
Indirect enzyme-linked immunosorbent assay (ELISA)
Complete cell lysates of BMMSCs were prepared using
RIPA buffer (Pierce). The protein amount was detected
with a BCA Protein Assay Kit (Pierce). 5 μg of total pro-
tein were used for ELISAs. 96-well plates were coated
with the samples overnight at 4°C using BupH coating
buffer (Pierce). The coated wells were blocked for 1 h at
room temperature (5% nonfat dry milk in PBS). Primary
antibodies were diluted in blocking buffer and incuba-
tion was performed overnight at 4°C (cyclin D1 and p21
1:500 (Cell Signaling); cyclin E (sc-481) 1:100 (Santa Cruz);
CDKN2A 1:200 (Thermo Scientific)). Between the incuba-
tion steps the wells were washed three times with PBS con-
taining 0.1% Tween. The secondary antibody (anti-rabbit
IgG-HRP (Cell Signaling)) was diluted 1:1000 and incuba-
tion was performed for 2 h at room temperature. Detection
was performed with TMB substrate (Pierce) and absorption
was measured at 450 nm. All measurements were per-
formed with three technical replicates. A dilution series
of complete cell lysates of the HS-5 cell line was used
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fication of protein levels. Pure RIPA buffer served as
negative control.
Statistical analysis
All experiments were statistically analyzed using GraphPad
Prism 6 software (LA Jolla, CA, USA). The data shown
represents the mean ± standard error of the mean (SEM).
Comparisons of HD-BMMSCs with MM-BMMSCs were
performed using the Mann–Whitney U test. The Wilcoxon
signed-rank test was used for the analysis of co-cultures
and transwell cultures. The unpaired/paired t-test was used
for statistical analysis of protein level results (ELISA ana-
lysis). Transfection experiments were analyzed using the
paired t-test. Results were considered statistically signifi-
cant when p ≤ 0.05.
Results
BMMSCs from MM patients at the time of diagnosis are
referred to as ND-MM-BMMSCs and BMMSCs from re-
lapsed MM patients are referred to as R-MM-BMMSCs.
For both analysis groups the abbreviation MM-BMMSCs
is used. BMMSCs from healthy donors are referred to as
HD-BMMSCs. Because ND-MM-BMMSCs and R-MM-
BMMSCs showed a similar mRNA expression, no separ-
ate analysis of ND-MM-BMMSCs and R-MM-BMMSCs
was performed for protein tests.
Given that the observed changes in ND-MM-BMMSCs
and R-MM-BMMSCs upon co-cultivation with KMS12-
PE myeloma cells were similar the data of co-cultures,
transwell cultures and microRNA transfection experi-
ments of both groups were combined to one analysis
group (MM-BMMSCs).
MM-BMMSCs exhibit a higher senescence state than
HD-BMMSCs
In contrast to HD-BMMSCs, MM-BMMSCs displayed a
2- to 3-fold (p < 0.005) higher SA-βGalA in passage 1
and 4 of the cell cultures (Figure 1A). R-MM-BMMSCs
had a 1.4-fold increased SA-βGalA as compared to ND-
MM-BMMSCs. These results could be confirmed by a
histological β-galactosidase staining of HD-BMMSCs
and MM-BMMSCs in passage 4 (Figure 1B). Furthermore,
qPCR analyses showed a 2.5- to 4-fold lower expression of
cyclin E1 and a 5- to 6-fold overexpression of cyclin D1 in
ND-MM-BMMSCs and R-MM-BMMSCs compared to
HD-BMMSCs (p < 0.05; Figure 1C). In addition, the cell
cycle inhibitor p21 was 2.5-fold upregulated in MM-
BMMSCs compared to HD-BMMSCs (p < 0.05) against
what no changes in the mRNA level of p16 were detected.
Similar differences between HD-BMMSCs and MM-
BMMSCs were detected at the protein level (Figure 1D).
Cyclin E1 was 2.8-fold decreased in MM-BMMSCs com-
pared to HD-BMMSCs (p = 0.0416). In contrast, cyclin D1and p21 protein levels were 1.5-fold to 1.8-fold increased.
Protein measurement showed also a slightly reduced level
of p16 in MM-BMMSCs but this change was below 1.5-
fold. These results correlated with a higher amount of
cells in S phase and a reduced amount of cells in G1/G0
phase compared to HD-BMMSCs (p < 0.008; Figure 1E).
MicroRNAs in MM-BMMSCs are aberrantly expressed
To investigate whether senescence of MM-BMMSCs is
correlated with changes in the microRNA expression, the
level of different microRNAs was analyzed using qPCR.
We chose six microRNAs, which were previously reported
to be deregulated in MM cells and to play a possible role
in the generation of senescence or cell cycle arrest (miR-
16, miR-485-5p, miR-519d, miR-221, miR-126, miR-223).
Analysis revealed an overexpression of miR-16, miR-223,
miR-485-5p and miR-519d (all with p < 0.025) in MM-
BMMSCs compared to HD-BMMSCs. No expression
differences were detected for miR-221 and miR-126
(Figure 2A).
MM-BMMSCs show hypomethylation and copy number
accumulation of the DLK1-DIO3 and C19MC genomic
clusters
qPCR analysis revealed the overexpression of miR-485-
5p and miR-519d in MM-BMMSCs. These microRNAs
are located on two imprinted clusters on chromosomes
14 (DLK1-DIO3) and 19 (C19MC), respectively, and are
reported to play a role in senescence generation [21,31,32].
Given that expression of both clusters is controlled by
methylation of their regulatory regions, we analyzed their
methylation status using qMSP (Figure 2B).
Hypomethylation of both clusters in MM-BMMSCs
compared to HD-BMMSCs was observed (Figure 2C).
For DLK1-DIO3, MM-BMMSCs exhibited an approxi-
mate 5-fold lower methylation level of the IG-DMR.
ND-BMMSCs methylation levels were not statistically
different for C19MC (p = 0.0537). However, they exhib-
ited the same characteristics as for R-MM-BMMSCs
(p = 0.0062) with a 2.5-fold lower methylation level com-
pared to HD-BMMSCs.
Another reason for the overexpression of miR-485-5p
and miR-519d could be CN variations of C19MC and
DLK1-DIO3. CN variation analysis was carried out at
three regions along each cluster (Figure 2B).
MM-BMMSCs displayed high levels of amplification
of the backward region of C19MC (Figure 2D). Error bars
indicate the detection of individual MM-BMMSCs with a
CN >7. The front and middle regions of C19MC exhibited
3 to 4 copies in MM-BMMSCs whereas in HD-BMMSCs
detected CNs were below 2.7 (p < 0.05). DLK1-DIO3 was
also commonly amplified, especially the front and the back
regions (Figure 2E). Copy number alterations for R-MM-
BMMSCs in the middle region of DLK1-DIO3 were not
Figure 1 MM-BMMSCs exhibit a higher senescence state than HD-BMMSCs. Asterisks indicate p-values with * <0.05, ** < 0.01, *** < 0.001
and **** < 0.0001. All data were analyzed using Mann–Whitney U test and unpaired t-test (ELISA analysis). (A) Flow cytometric analysis of
SA-βGalA. ND-MM-BMMSCs (n = 12) and R-MM-BMMSCs (n = 9) displayed higher activity of SA-βGal in passage 1 and 4 of cell cultures compared
to HD-BMMSCs (n = 8). (B) Histological analysis of SA-βGalA. MM-BMMSC (59 years) showed aproximately 17 cells with high SA-βGalA compared
to HD-BMMSC (67 years) with only 10 cells. Positive cells are indicated by arrows. (C) QPCR analysis displayed decreased cyclin E1, increased cyclin
D1 and p21 expression in ND-MM-BMMSCs (n = 24) and R-MM-BMMSCs (n = 21) compared to HD-BMMSCs (n = 10). (D) Measurement of protein
level in HD-BMMSCs (n = 2) and MM-BMMSCs (n = 3). Cyclin E1 was significantly decreased in MM-BMMSCs compared to HD-BMMSCs whereas
cyclin D1 and p21 were increased. The protein amount of p16 was slightly reduced in MM-BMMSCs compared to HD-BMMSCs. (E) Cell cycle
analysis showed a higher amount of cell in S phase in ND-MM-BMMSCs (n = 11) and R-MM-BMMSCs (n = 5) compared to HD-BMMSCs (n = 6).
Percentage of cells in G1/G0 phase was lower compared to HD-BMMSCs.
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Figure 2 Overexpressed microRNAs in MM-BMMSCs are associated with hypomethylation and CN accumulation of DLK1-DIO3 and
C19MC. Asterisks indicate p-values with * <0.05, ** < 0.01, *** < 0.001 and **** < 0.0001. All data were analyzed using Mann–Whitney U test.
(A) ND-MM-BMMSCs (n = 24) and R-MM-BMMSCs (n = 21) showed high overexpression of miR-16, miR-485-5p, miR-519d and miR-223 compared
to HD-BMMSCs (n = 10). (B) Schematic presentation of the genomic organization of DLK1-DIO3 on chromosome 14 (C14q32) and C19MC on
chromosome 19 (C19q13.41). Circles indicate the regulatory region of the respective cluster and arrows point to positions of CN measurement.
Modified from Morales-Prieto et al. [27] (C) The regulatory regions of DLK1-DIO3 and C19MC were hypomethylated in ND-MM-BMMSCs (n = 25)
and R-MM-BMMSCs (n = 18) compared to HD-BMMSCs (n = 9). (D) CN analysis of C19MC displayed CN accumulation in all three regions in
ND-MM-BMMSCs (n = 23) and R-MM-BMMSCs (n = 15) compared to HD-BMMSCs (n = 8). (E) CN analysis of DLK1-DIO3 displayed CN accumulation
in all three measured positions in MM-BMMSCs compared to HD-BMMSCs (sample number as indicated in (D)). No accumulation was measured
for R-MM-BMMSCs in position 2.
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ited significant amplification (p = 0.0065).
KMS12-PE myeloma cells reduce SA-βGalA and modify
cell cycle characteristics of MM-BMMSCs
Co-cultures and transwell cultures of the KMS12-PE cell
line with MM-BMMSCs were carried out to analyze
whether MM cells can exert an influence on the senes-
cence characteristics of MM-BMMSCs (Figure 3A). When
co-cultured with myeloma cells MM-BMMSCs exhibited a
reduced SA-βGalA compared to the same MM-BMMSCs
cultured alone (median fluorescence intensity (MFI) of
118.1 vs. 178.4; p < 0.0001). A similar effect could be
detected using transwell cultures to prevent cell-cell-
contact between MM-BMMSCs and KMS12-PE cells
(MFI of 173 vs. 267.3; p < 0.0313). No effect on the activity
of SA-βGal was observed in HD-BMMSCs and the HS-5
cell line co-cultured with KMS12-PE myeloma cells. In
addition, mRNA expression of co-cultured and transwell
cultured MM-BMMSCs was measured (Figure 3B). No
effect could be detected for cyclin D1 and p16, whereas
cyclin E1 was 3.25-fold upregulated in co-cultured and
1.6-fold upregulated in transwell cultured MM-BMMSCs
(p < 0.05). Surprisingly, cell interaction with MM cells also
induced an upregulation of p21 mRNA in MM-BMMSCs.
This effect was lower in transwell cultured MM-BMMSCs
compared to co-cultured MM-BMMSCs (1.9-fold and 3-
fold; p < 0.008). However, contrary results were detected
at protein level showing a 1.7-fold reduction of p21 in co-
cultured MM-BMMSCs (Figure 3C). In addition, cyclin
D1 protein expression was 1.8-fold reduced upon co-
cultivation with KMS12-PE myeloma cells whereas no
change was seen on mRNA level (p = 0.0033). In contrast,
the mRNA and protein analysis of cyclin E1 and p16 was
concordant. Co-cultured MM-BMMSCs displayed also 2-
fold upregulation of cyclin E1 on protein level against
what the protein level of p16 was unchanged. In this
context cell cycle distribution of co-cultured and trans-
well cultured MM-BMMSCs was analyzed (Figure 3D).
Both cell culture systems led to a slight reduction of
cells in S phase compared to MM-BMMSCs cultured
alone (p = 0.0078). Furthermore, a light increase of cellsin G1/G0 phase was detected for co-cultured MM-
BMMSCs compared to MM-BMMSCs cultured alone
(p = 0.0078). Transwell cultured MM-BMMSCs showed
the same tendency but significant changes were not
detectable.Cell interaction between KMS12-PE myeloma cells and
MM-BMMSCs induces changes of microRNA expression
in both cell types
To explore whether changes in senescence and cell cycle
characteristics of MM-BMMSCs upon cultivation with
KMS12-PE cells are associated with changes in the micro-
RNA level of overexpressed microRNAs (miR-16, miR-223,
miR-485-5p and miR-519d), the microRNA expression of
co-cultured and transwell cultured MM-BMMSCs was
measured using qPCR (Figure 4A). Significant changes
were detected for miR-223 and miR-485-5p. MiR-223
was 3-fold downregulated in co-cultured MM-BMMSCs
(p < 0.007), whereas no effect was detected in transwell
cultured MM-BMMSCs. In contrast, downregulation of
miR-485-5p was detected in both cell culture systems,
whereby the effect reduced from 4-fold in co-cultured
MM-BMMSCs to 2-fold in transwell cultured MM-
BMMSCs (p < 0.03). Interestingly, cell-cell-interaction also
altered microRNA expression of KMS12-PE myeloma
cells. MiR-221 increased 13.78-fold whereas miR-223 and
miR-519d were 2.72- to 2.85-fold reduced in co-cultured
KMS12-PE myeloma cells (p < 0.02, Figure 4B). Expres-
sion of miR-485-5p was not detectable in KMS12-PE
myeloma cells.
Furthermore, we analyzed whether changes in the
methylation status of the DLK1-DIO3 regulatory region
upon co-cultivation with KMS12-PE cells could be the
reason for changes in miR-485-5p expression (Figure 4C).
In co-cultured MM-BMMSCs a significant increase in
the percentage IG-DMR methylation compared to MM-
BMMSCs cultured alone was detected (14.31 ± 3.741%
vs. 9.931 ± 2.21%; p < 0.004). In contrast, no CN varia-
tions of DLK1-DIO3 in co-cultured MM-BMMSCs com-
pared to MM-BMMSCs cultured alone were detected
(data not shown).
Figure 3 KMS12-PE myeloma cells reduce SA-βGalA and modify cell cycle characteristics of MM-BMMSCs. Asterisks indicate indicate
p-values with * <0.05, ** < 0.01, *** < 0.001 and **** < 0.0001. All data were analyzed using Wilcoxon signed-rank test and paired t-test (ELISA
analysis). (A) KMS12-PE myeloma cells reduce SA-βGalA in MM-BMMSCs upon co-cultivation (n = 20) and cultivation in transwells (n = 6). (i) The
MFI in MM-BMMSCs was significantly reduced in both culture systems. No changes were observed for co-cultured HD-BMMSCs (n = 3) and
HS-5 cells (n = 3) indicating specificity of the measured effect for MM-BMMSCs. (ii) Representative histogram of a co-cultured MM-BMMSC
and transwell-cultured MM-BMMSC population compared to the same MM-BMMSC population cultured alone. (B) Cell interaction with
KMS12-PE myeloma cells induced increased cyclin E1 and p21 expression in MM-BMMSCs compared to MM-BMMSCs cultured alone (co-culture
n = 25, transwell culture n = 10). (C) Protein expression analysis of co-cultured MM-BMMSCs (n = 3) compared to mono-cultured MM-BMMSCs.
Cyclin E1 was increased whereas cyclin D1 and p21 were reduced in co-cultured cells compared to mono-cultures. No change was seen for p16.
(D) Cell interaction with KMS12-PE myeloma cells induced an increase of cells in G1/G0 phase and reduced the amount of cells in S phase in
co-cultured and transwell cultured MM-BMMSCs (n = 8) compared to the same MM-BMMSCs cultured alone.
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To explore whether downregulation of miR-485-5p is as-
sociated with the reduction of cells in S phase and SA-βGalA of MM-BMMSCs, transfections with miR-485-5p
mimic or inhibitor were performed. Transient overexpres-
sion of miR-485-5p induced a reduction of SA-βGalA,
whereas the inhibition of miR-485-5p led to an increase in
Figure 4 KMS12-PE myeloma cells downregulate miR-223 and
miR-485-5p in MM-BMMSCs. Asterisks indicate indicate p-values
with * <0.05, ** < 0.01, *** < 0.001 and **** < 0.0001. All data were
analyzed using Wilcoxon signed-rank test. (A) Co-cultured MM-BMMSCs
(n = 25) displayed reduced expression of miR-223 and miR-485-5p.
Transwell-cultured (n = 10) MM-BMMSCs showed no changes in
miR-223 expression but also decreased miR-485-5p levels. Intensity
of changes in miR-485-5p decreased when cell-cell-contact was
prevented by transwell cultivation. (B) Cell interaction with
MM-BMMSCs induced changes in the microRNA expression of
KMS12-PE myeloma cells (n = 10). MiR-221 was upregulated
whereas miR-223 and miR-519d decreased in co-cultured KMS12-PE
myeloma cells. (C) Cell interaction with KMS12-PE myeloma cells
led to increased methylation of the IG-DMR of DLK1-DIO3 as
measured by qMSP (n = 9).
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trols (p < 0.05; Figure 5A). Overexpression of miR-485-5p
had no effect on the cell cycle of MM-BMMSCs (data not
shown), whereas inhibition of miR-485-5p induced differ-
ent effects in MM-BMMSCs. Three MM-BMMSCs out of
five transfected with the miR-485-5p inhibitor showed a
decrease of cells in S phase and a significant increase of
cells in G1/G0 phase compared to the controls (p < 0.003;
Figure 5B). In contrast, two MM-BMMSCs displayed an
inverse effect with an increase of cells in S phase and a
decrease of cells in G1/G0 phase (p < 0.008; Figure 5C).
These diverse results displayed no correlation with the
ND-MM-BMMSCs or R-MM-BMMSCs characteristic.
Discussion
MM-BMMSCs play a critical role in MM tumor growth
and survival. Several studies suggest the existence of
senescence-associated constitutive abnormalities in MM-
BMMSCs, and that these lead to abnormal cell character-
istics and increased tumor support [11-13,15,42,43]. In
this study we investigated the correlation between sen-
escence and microRNA expression in MM-BMMSCs
and the influence of MM cells on these alterations.
In vitro cultured MM-BMMSCs showed increased sen-
escence and accumulation of cells in S phase. These char-
acteristics were associated with a reduced cyclin E1 and an
increased cyclin D1 expression. R-MM-BMMSCs showed
a higher SA-βGalA compared to ND-MM-BMMSCs.
Therefore, it seems that relapse of MM could increase
the premature senescence phenotype of MM-BMMSCs.
In addition, the increased activity of SA-βGalA could be
associated with the prolonged disease progression which
is present in relapsed patients. As previously described
we found overexpression of p21 but not p16 pointing to
DNA damage mediated senescence [15]. Though senes-
cence of MM-BMMSCs was already reported the rea-
sons for this cellular state are not clear [12,14,15,43].
MicroRNAs are potential regulators of senescence but
data relating to microRNA expression in MM-BMMSCs
Figure 5 miR-485-5p influences senescence and cell cycle characteristics of MM-BMMSCs. Asterisks indicate indicate p-values with * <0.05,
** < 0.01, *** < 0.001 and **** < 0.0001. All data were analyzed using the paired t-test. (Ai) Transient overexpression of miR-485-5p led to reduced
SA-βGalA whereas inhibition of miR-485-5p increased SA-βGalA. (ii) Representative histograms showing the effect of miR-485-5p inhibitor
(n = 5) and miR-485-5p mimic (n = 5) on SA-βGalA in MM-BMMSCs compared to the transfection and negative control. (Bi) In three out of five
transfected MM-BMMSCs the inhibition miR-485-5p induced the reduction of cells in S phase and accumulation of cells in G1/G0 phase of the
cell cycle. (ii) Representative histogram showing one effect on the cell cycle of MM-BMMSCs induced by the inhibition of miR-485-5p. Reduced
amount of cells in S phase is shown. (Ci) Two out of five transfected MM-BMMSCs displayed increased cells in S phase and reduced cells in G1/G0
phase upon transfection with the miR-485-5p inhibitor. (ii) Representative histogram showing the reverse effect on the cell cycle of MM-BMMSCs
induced by the inhibition of miR-485-5p. Increased amount of cells in S phase is visible.
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of the microarray data from MM cells were analyzed
[29]. Overexpression was found for miR-223, which was
also overexpressed in MM cells. Furthermore miR-16,
miR-485-5p and miR-519d were overexpressed in MM-
BMMSCs whereas these microRNAs were downregulated
in MM cells. Previous studies have identified miR-16 as a
tumor suppressor in leukemic cells and its overexpression
in MM-BMMSCs could induce a similar effect [45]. In
contrast, no specific functions of miR-223, miR-485-5p
and miR-519d in MM are known. MiR-485-5p and miR-
519d, which are expressed on the clusters DLK1-DIO3
and C19MC, were reported to play a role in senescence
generation [21,32,46,47]. The regulatory regions of both
clusters were hypomethylated together with CN accumu-
lation of the genomic regions in MM-BMMSCs. These
two alterations could be responsible for the overexpres-
sion of miR-485-5p and miR-519d. The aberration of
genomic CN also points to genomic alterations in MM-
BMMSCs possibly explaining the p21-associated senes-
cence state. In addition, Abdeolmohsen et al. reported that
miR-519 promotes DNA damage and elevates the level of
p21 [32].
Next, we analyzed whether cell interaction with MM
cells influences these alterations. Surprisingly, cell inter-
action with KMS12-PE cells led to reduced SA-βGalA
and cells in S phase of the cell cycle. This effect was also
seen when cell-cell-contact was prevented by transwells.
Thus, the increase of cells in G1/G0 phase points to a pro-
proliferative influence of MM cells on MM-BMMSCs.
This shift in the cell cycle characteristics could also be the
reason for the decreased cyclin D1 expression and the
increased expression of cyclin E1 in co-cultured MM-
BMMSCs. Noll et al. reported that MM cells alter the
microenvironment of MM by supporting the proliferation
of mesenchymal stem cells through soluble factors as IL-6
[48]. Therefore oncogenic signaling by MM cells by differ-
ent cytokines could induce the reversal of senescence in
MM-BMMSCs [49]. In addition, the reduction of SA-
βGalA was accompanied by a reduction of p21 at the
protein level. In contrast, p21 mRNA expression was in-
creased. The mRNA amount is not a direct reflection of
protein expression since post-transcriptional processes
are significant to the final synthesis of proteins. Con-
trary expression levels of mRNA and proteins could be
of interest for the understanding of the interaction be-
tween myeloma cells and BMMSCs in MM pathogen-
esis. Here, it could be induced by a feedback mechanism
activated through the depletion of p21 at the protein
level. In addition, the reversal mechanisms of senes-
cence are still not clear [17,18]. Even though senescence
in MM-BMMSCs seems to be generated by increased
p21 expression it is possible that reversal of this cellular
state is mediated by a distinct signaling pathway [31,45].Cell interaction with MM cells reduced levels of miR-
223 and miR-485-5p in MM-BMMSCs. Given that only
miR-485-5p was also reduced when cell-cell-contact
between MM-BMMSCs and MM cells was prevented,
this microRNA was a potential candidate for modulation
of senescence in MM-BMMSCs. In addition, cell inter-
action seems to increase methylation of the IG-DMR of
DLK1-DIO3 possibly leading to reduced expression of the
cluster-associated microRNAs [50]. Interaction of KMS12-
PE myeloma cells with MM-BMMSCs also induced micro-
RNA changes in the MM cell fraction. Cell-cell-interaction
strongly increased the level of miR-221 in KMS12-PE
myeloma cells. This microRNA acts as an oncogene by
downregulation of different cell cycle inhibitors leading to
an increased tumor cell proliferation [51]. In addition,
miR-223 and miR-519d were downregulated in co-cultured
KMS12-PE myeloma cells. As previously mentioned these
microRNAs could have anti-proliferative effects on cells
[21,32,46,47]. Therefore, interaction with MM-BMMSCs
seems to shift microRNA levels of KMS12-PE myeloma
cells towards a more pro-proliferative gene expression
pattern.
Finally, MM-BMMSCs were transfected with miR-485-
5p mimic or inhibitor. The effect on SA-βGalA was con-
trary to the one seen by cell interaction with MM cells
because increased miR-485-5p levels decreased the SA-
βGalA and vice versa. This indicates that miR-485-5p
alone is not responsible for reversal of senescence in
MM-BMMSCs but additional genetic events are needed.
This could be based on the fact that increased methylation
of the IG-DMR of DLK1-DIO3, which possibly leads to
reduced transcription of this genomic region, controls all
associated microRNAs. Therefore, the mechanism which
induces the observed effect in MM-BMMSCs upon cell
interaction with MM cells could be rather complex. Inter-
estingly, inhibition of miR-485-5p also induced different
cell cycle effects in MM-BMMSCs. Three of the trans-
fected MM-BMMSCs displayed an effect which was
similar to the one induced by cell interaction with MM
cells, whereas the other two showed a contrary cell cycle
change. This again indicates that miR-485-5p acts in de-
pendence of additional molecular genetic events or cel-
lular properties [47].
Although manipulation of miR-485-5p alone could not
mimic the effect on SA-βGalA and the cell cycle of MM-
BMMSCs upon cell interaction with MM cells, the results
strongly indicate that miR-485-5p and the associated clus-
ter DLK1-DIO3 participate in the regulation of senescence
and cell cycle characteristics in MM-BMMSCs. Therefore,
further investigations of this topic are needed. Further-
more, the premature senescence phenotype of MM-
BMMSCs seems to be an attendant phenomenon rather
than a specific tumor supportive stromal cell character-
istic. The reduction of the senescence phenotype by
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MM-BMMSCs does not rely on this cell characteristic.
It is likely that MM cells benefit from a more vital cellu-
lar state of MM-BMMSCs. Therefore, the premature
senescence phenotype of MM-BMMSCs could be a side
effect possibly induced through increased activation of
stromal cells by MM cells. However, further analysis is
needed to determine whether the senescence-associated
constitutive changes of MM-BMMSCs could support
relapse of MM disease.
Conclusions
In summary we found that senescence in MM-BMMSCs is
associated with the overexpression of potential senescence-
mediating microRNAs and copy number variations of
DLK1-DIO3 and C19MC. This is the first report indicating
that the senescence phenotype of MM-BMMSCs is par-
tially reversed by cell interaction with MM cells and it is
therefore not clear whether this phenotype could in vivo
be important for the pathogenesis of active MM disease or
is more important when cell interaction of MM-BMMSCs
with MM cells is inhibited. More investigations regard-
ing the role of senescence of MM-BMMSCs in MM
could lead to new insights for the improvement of ther-
apy efficiency and follow-up treatment of MM patients.
The genomic region of DLK1-DIO3 includes potential
senescence-modulating microRNAs and further analysis
of the role of DLK1-DIO3 and the associated micro-
RNAs could reveal new insights into the genetic events
that senescence relies on.
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